© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
13. MinerM,NehraA, JacksonGet al.Allmenwithvasculogenic ED
require a cardiovascular workup.
Am J Med
2014;127(3):174-182.
14. Alberti KG, Eckel RH, Grundy SM et al. International
Diabetes Task Force on Epidemiology and Prevention,
National Heart, Lung and Blood Institute, American
Heart Association, World Heart Federation, International
Atherosclerosis Society, International Association for the
Study of Obesity: harmonizing the metabolic syndrome: a
joint interim statement of the International Diabetes Task
Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; AmericanHeartAssociation; World
Heart Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity.
Circulation
2009;120(16):1640-1645.
15. Kassi E, Pervanidou P, Kaltsas G et al. Metabolic syndrome:
definitions and controversies.
BMC Med
2011;9:48-61.
16. Aslan Y, Sezgin T, Tuncel A et al. Is type 2 diabetes mellitus a
cause of severe erectile dysfunction in patients withmetabolic
syndrome.
Urology
2009;74(3):561-564.
17. Demir T, Demir O, Kefi A et al. Prevalence of erectile
dysfunctioninpatientswithmetabolicsyndrome.
IntJUrol
2006;
13(4):385-388.
18. Bal K, OderM, SahinAS et al. Prevalence ofmetabolic syndrome
and its association with erectile dysfunction among urologic
patients: metabolic backgrounds of erectile dysfunction.
Urology
2007;69(2):356-360.
19. El‑Sakka AI, Morsy AM. Screening for ischemic heart disease
in patients with erectile dysfunction: role of penile Doppler
ultrasonography.
Urology
2004;64(2):346-350.
20. El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary
artery risk factors in patients with erectile dysfunction.
J Urol
2004;172(1):251-254.
21. Jackson G. Sexual response in cardiovascular disease.
J Sex Res
2009;46(2-3):233-236.
22. Al‑HunayanA,Al‑MutarM,KehindEO,ThalibL,Al‑GhororyM.
The prevalence and predictors of erectile dysfunction in men
withnewlydiagnosedwithtype2diabetesmellitus.
BJUInt
2007;
99(1):130-134.
23. Tomada N, Tomada I, Botelho F, Cruz F, Vendeira P. Are
all metabolic syndrome components responsible for penile
hemodynamics impairment in patients with erectile
dysfunction? The role of body fat mass assessment.
J Sex Med
2011;8(3):831-839.
24. Kupelian V, Shabsig R, AraujoAB, O’Donell AB, McKinlay JB.
Erectile dysfunction as a predictor of the metabolic syndrome
in agingmen: results from theMassachusettsmale aging study.
J Urol
2006;176(1):222-226.
25. Corona G, Mannucci E, Ricca V et al. The age‑related decline of
testosterone is associatedwith different specific symptoms and
signs inpatientswith sexual dysfunction.
Int J Androl
2009;32(6):
720-728.
26. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome
and urologic diseases.
Rev Urol
2010;12(4):157-180.
27. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic
regulationofNOavailability in rat penile erection.
J Androl
1997;
18(2):110-115.
28. Chen C J, Kuo TB, Tseng, YJ, Yang CC. Combined cardiac
sympathetic excitation and vagal impairment in patients with
non‑organic erectile dysfunction.
ClinNeurophysiol
2009;120(2):
348-352.
29. Kirby RS, O’Leary MP, Carson C. Efficacy of extended‑release
doxazosin anddoxazosin standard inpatientswith concomitant
benign prostatic hyperplasia and sexual dysfunction.
BJU Int
2005;95(1):103-109.
30. De Rose AF, Carmignani G, Corbu C et al. Observational
multicentric trial performedwithdoxazosin: evaluationof sexual
effects onpatientswithdiagnosed benignprostatic hyperplasia.
Urol Int
2002;68(2):95-98.
31. Liguori G, Trombetta C, De Giorgi G et al. Efficacy of combined
oraltherapywithtadalafilandalfuzosin:anintegratedapproach
tomanagement of patients with lower urinary tract symptoms
and erectile dysfunction. Preliminary report.
J Sex Med
2009;
6(2):544-552.
32. Kaplan SA, Gonzeles RR, Te AE. Combination of alfuzosin
and sildenafil is superior to monotherapy in treating lower
urinary tract symptoms and erectile dysfunction.
Eur Urol
2007;
51(6):1717-1723.
33. Rosen R, Altwein J, Boyle P et al. Lower urinary tract
symptoms and male sexual dysfunction: the multinational
survey of the aging male (MSAM‑7).
Eur Urol
2003;44(6):
637-649.
34. McVary K. Lower urinary tract symptoms and sexual
dysfunction: epidemiology and pathphysiology.
BJU Int
2006;
97(Suppl 2):23-28.
35. De Rose AF, Carmignani G, Corbu C et al. Observational
multicentric trial performedwithdoxazosin: evaluationof sexual
effects on patients with diagnosed benign prostatic hyperplasia.
Urol Int
2002;68(2):95-98.
36. Faris JE, Smith MR. Metabolic sequele associated with
androgen deprivation therapy for prostate cancer.
Curr Opin
Endocrinol Diabetes Obes
2010;17(3):240-246.
37. Hammarsten J, Peeker R. Urologic aspects of the metabolic
syndrome.
Nat Rev Urol
2011;8(9):483-494.
38. Cohen PG. Obesity inmen: the hypogonadal‑ estrogen receptor
relationship and its effect on glucose homeostasis.
Med
Hypotheses
2008;70(2):358-360.
39. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G.
Attenuated luteinizing hormone (LH) pulse amplitude but
normal pulse frequency, and its relation to plasma androgens
in hypogonadism of obese men.
J Clin Endocrinol Metab
1993;
76(5):1140-1146.
40. Cohen PG. The role of estradiol in the maintenance of
secondary hypogonadism in males in erectile dysfunction.
Med Hypotheses
1998;50(4):331-333.
41. ZumoffB,MillerLK,StrainGW.Reversalofthehypogonadotropic
hypogonadismof obesemen by administration of the aromatase
inhibitor testolactone.
Metabolism
2003;52(9):1126-1128. 42.
Rosmond R., Dallman MF, Björntorp P. Stress‑related cortisol
secretion in men: relationships with abdominal obesity and
endocrine, metabolic and hemodynamic abnormalities.
J Clin
Endocrinol Metab
1998;83(6):1853-1859.
43. Chrousos G.P. Stressors, stress, and neuroendocrine
integration of the adaptive response. The 1997 Hans Selye
Memorial Lecture.
Ann NY Acad Sci
1998;851:311-335.
44. Araujo AB, Hall SA, Ganz P et al. Does erectile dysfunction
contribute to cardiovascular disease risk prediction beyond the
Framingham risk score?
J Am Coll Cardiol
2010;55(4):350-356.
45. Thompson IM, Tamgen CM, Goodman PJ, Probstfield JL,
Moinpour CM, Coltman CA. Erectile dysfunction and
subsequentcardiovasculardisease.
JAMA
2005;294(23):2296-3002.
46. Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction
as a predictor of cardiovascular events and death in diabetic
patients with angiographically proven asymptomatic coronary
artery disease: a potential protective role for statins and
5-phosphodiesterase inhibitors.
J Am J Cardiol
2008;51(21):
2040-2044.
47. MaRC,SoWY,YangXetal.Erectiledysfunctionpredictscoronary
artery disease in type 2 diabetics.
J Am Coll Cardiol
2008;51(21):
2045-2050.
48. Schouten BW, BohnenAM, Bosch JL et al. Erectile dysfunction
prospectively associated with cardiovascular disease in the
Dutch general population: results from the Krimpen Study.
Int J Impot Res
2008;20(1):92-99.
49. WilsonPW, D’AgostinoRB, LevyD, et al. Predictionof coronary
heart diseaseusing risk factor categories.
Circulation
1998;97(18):
1837-1847.
36
Miner ET AL.
